Evidence map›Paper›PMID 33974158›Full record

ArticleClinical and experimental nephrology2021

Utility of remission criteria for the renal prognosis of IgA nephropathy.

Keiichi Matsuzaki, Hitoshi Suzuki, Tetsuya Kawamura, Yasuhiko Tomino, Yusuke Suzuki

Abstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental nephrology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Keiichi MatsuzakiDepartment of Nephrology, Juntendo University Faculty of Medicine, Hongo 2-1-1, Bunkyo-Ku, Tokyo, 113-8421, Japan.
Hitoshi SuzukiDepartment of Nephrology, Juntendo University Faculty of Medicine, Hongo 2-1-1, Bunkyo-Ku, Tokyo, 113-8421, Japan.
Tetsuya KawamuraDivision of Kidney and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-Shinbashi, Minato-Ku, Tokyo, 105-8461, Japan.
Yasuhiko TominoDepartment of Nephrology, Juntendo University Faculty of Medicine, Hongo 2-1-1, Bunkyo-Ku, Tokyo, 113-8421, Japan.
Yusuke SuzukiDepartment of Nephrology, Juntendo University Faculty of Medicine, Hongo 2-1-1, Bunkyo-Ku, Tokyo, 113-8421, Japan. yusuke@juntendo.ac.jp.

Funding

Japan Society for the Promotion of Science (JP) Grant-in-Aid for Early-Career Scientists (18K17380)
6 · The paper itself

Abstract

backgroundNovel criteria for the remission of Immunoglobulin A nephropathy (IgAN) based on an opinion survey of Japanese nephrologists and literature review were proposed in 2013. This single-center, longitudinal retrospective cohort study was conducted to validate this criteria.

methodsPresent study included the IgAN patients diagnosed between 2001 and 2005 in the Juntendo University Hospital. Remission of hematuria was defined as three consecutive dipstick test results of ( -) to ( ±) or a red blood cell count < 5 in urinary sediment per high-power field during at least 6 months. Remission of proteinuria was defined as three consecutive dipstick results of ( -) to ( ±) during at least 6 months. We categorized four groups according to the remission status which was assessed 2 years after the renal biopsy. The primary outcome was a 50% increase in the serum creatinine over the baseline. We evaluated the slope of eGFR decline (mL/min/1.73 m

resultsA total of 74 patients (male: 47.3%, median age: 30 years) were included and were followed for a median of 86.5 months. During the period, forty-one patients achieved neither remission of proteinuria nor hematuria (NR). Twelve patients met the primary study outcome. A survival analysis revealed that the NR had the worst prognosis and the steepest slope of eGFR decline.

conclusionAlthough further validation in a large cohort is necessary, these novel remission criteria for IgAN patients appear to predict the renal prognosis.

Indexed as

Remission InductionAdultCombined Modality TherapyCreatinineDisease ProgressionFemaleGlomerular Filtration RateGlomerulonephritis, IGAHematuriaHumansLongitudinal StudiesMaleMiddle AgedPrognosisProteinuriaRetrospective StudiesCreatinineSteroidsIgA nephropathyRemission criteriaRenal prognosis

Identifiers

PMID33974158
PMCPMC8357773

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.